Significant variability in symptoms and disease burden exists among myasthenia gravis patients across MGFA classes, challenging the use of MGFA classification for individual prognosis. Many patients ...
SAVANNAH, Ga. -- Inebilizumab (Uplizna) had clinically meaningful efficacy and a favorable safety profile among people with generalized myasthenia gravis (gMG), topline data from the MINT trial showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback